DLinDMA is a key lipid component of stable nucleic acid lipid particles as a benchmark. DLinDMA can be used to deliver siRNA[1].
DLinDMA liposomal formulation was nontoxic at lower concentrations. A significant decrease in cell proliferation was only observed at the highest concentration 200 µM for DOTAP and at concentrations ranging from 25 to 200 µM for DLinDMA liposomal formulations[2]. In a macrophage cell-line, LNP containing DLinKC2-DMA, DLinKDMA, or DLinDMA, which lack ester linkages, are not vulnerable to lipase digestion and facilitate much more potent gene silencing[3].
As a key lipid component of nucleic acid lipid granules (SNALP), DLinDMA can deliver small interfering RNA (siRNA) in mice[1].
References:
[1]. Semple SC, Akinc A,et,al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010 Feb;28(2):172-6. doi: 10.1038/nbt.1602. Epub 2010 Jan 17. PMID: 20081866.
[2]. Vemana HP, Saraswat A, et,al. A novel gene therapy for neurodegenerative Lafora disease via EPM2A-loaded DLinDMA lipoplexes. Nanomedicine (Lond). 2021 Jun;16(13):1081-1095. doi: 10.2217/nnm-2020-0477. Epub 2021 May 7. PMID: 33960213; PMCID: PMC8162161.
[3]. Lin PJ, Tam YY, et,al.Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA. Nanomedicine. 2013 Feb;9(2):233-46. doi: 10.1016/j.nano.2012.05.019. Epub 2012 Jun 12. PMID: 22698807.
DLinDMA 是以稳定的核酸脂质颗粒为基准的关键脂质组分。 DLinDMA 可用于递送 siRNA[1]。
DLinDMA 脂质体制剂在较低浓度下无毒。仅在 DOTAP 的最高浓度 200 µM 和 DLinDMA 脂质体制剂的浓度范围为 25 至 200 µM 时观察到细胞增殖显着下降[2]。在巨噬细胞系中，含有缺乏酯键的 DLinKC2-DMA、DLinKDMA 或 DLinDMA 的 LNP 不易被脂肪酶消化，并促进更有效的基因沉默[3]。
作为核酸脂质颗粒 (SNALP) 的关键脂质成分，DLinDMA 可以在小鼠体内递送小干扰 RNA (siRNA)[1]。